ArticleJournal of clinical medicine2021
Soluble ST2 and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease-A 10-Year Cohort Study.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti-ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies.Clinical and translational science · 2025Trial
- The role of soluble suppression of tumorigenicity 2 in pulmonary hypertension: a systematic review and meta-analysis.American heart journal plus : cardiology research and practice · 2026Review
- Mast cells and endothelial cells mediate interleukin-33 and ST2 responses in distal chronic obstructive pulmonary disease lungs.American journal of respiratory and critical care medicine · 2026Article
- Targeting IL-33 in COPD: mechanistic lessons from clinical trials and the path forward.Respiratory research · 2026Review
- Emerging targeted therapies for chronic obstructive pulmonary disease: from symptom control to precision medicine.Frontiers in pharmacology · 2026Review
- The Contingency of Reported sST2 Serum Concentrations with a Protein Detection System (ELISA) from the Same Manufacturer (R&D Biotechne, 2002-2025): An Explanatory Effort by Applied Medical Researchers.Diagnostics (Basel, Switzerland) · 2025Article
- IL-33 is associated with alveolar dysfunction in patients with viral lower respiratory tract disease.Mucosal immunology · 2025Article
- Is Disease Stability an Attainable Chronic Obstructive Pulmonary Disease Treatment Goal?American journal of respiratory and critical care medicine · 2025Review
- Serum IL-33/ST2 Axis Expression in Acute Exacerbations of COPD: Correlation with Pulmonary Function.International journal of chronic obstructive pulmonary disease · 2025Article
- Article
- Correlations between soluble ST2 concentration and the nutritional status in patients with heart failure with reduced ejection fraction - cross-sectional study.Cardiology journal · 2024Article
- Cardiac Radiofrequency Ablation Exacerbates Myocardial Injury through Pro-Inflammatory Response and Pro-Oxidative Stress in Elderly Patients with Persistent Atrial Fibrillation.Current vascular pharmacology · 2024Article
- Role of IL-33-ST2 pathway in regulating inflammation: current evidence and future perspectives.Journal of translational medicine · 2023Review
- Exploring Mechanisms in COPD: Time for Biomarker Reappraisal?Journal of clinical medicine · 2023Article
- Soluble ST2 in Patients with Carotid Artery Stenosis-Association with Plaque Morphology and Long-Term Outcome.International journal of molecular sciences · 2023Article
- Predictive Value of GDF-15 and sST2 for Pulmonary Hypertension in Acute Exacerbation of Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2023Article
- Novel Biomarkers in Lung Cancer and Chronic Lung Diseases: From the Systematic Perspective ofJournal of clinical medicine · 2022Article
- Prognostic value of interleukin-33, sST2, myeloperoxidase, and matrix metalloproteinase-9 in acute aortic dissection.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is an inflammatory condition with constantly increasing mortality rates. Interleukin (IL)-33 and its decoy receptor, soluble suppression of tumorigenicity 2 (sST2), play a central role in the inflammatory response during infection. sST2 was suggested as a factor in the pathogenesis of COPD and emerged as a predictor of mortality in other non-communicable diseases. The role of sST2 as a predictor of mortality remains unclear in COPD yet. In this cohort study, we measured circulating concentrations of IL-33 and sST2 in the serum of patients with stable COPD (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.